semaglutide 1 mg for superiority, adjusted for multiplicity
Mayo Clinic notes that approximately 25% to 40% of weight lost during GLP-1 therapy may come from lean mass (which includes water, organs, bone, connective tissue, and skeletal muscle, not muscle alone)
Where do you see it going
Collectively, co-targeting metabolic dependencies (e.g., glutaminase inhibitors, ammonium scavengers) and death evasion mechanisms (e.g., ferroptosis inducers, ATF6 inhibitors) may overcome therapeutic resistance, with preclinical validation urgently needed for strategies combining autophagy modulation (AMPK/mTOR/ULK1 targeting), ferroptosis potentiation (system Xc blockade), and stromal disruption (CAF-derived glutamine inhibition) (205, 206)
Of note, the TGF/SMAD3 signaling pathway is involved in endometrial fibrosis and is thought to play an important role in adenomyosis pathobiology [74, 75]
Combining genetic insights with baseline biomarker data creates a more complete picture for your provider